BR112015027528A2 - polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira - Google Patents

polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira

Info

Publication number
BR112015027528A2
BR112015027528A2 BR112015027528A BR112015027528A BR112015027528A2 BR 112015027528 A2 BR112015027528 A2 BR 112015027528A2 BR 112015027528 A BR112015027528 A BR 112015027528A BR 112015027528 A BR112015027528 A BR 112015027528A BR 112015027528 A2 BR112015027528 A2 BR 112015027528A2
Authority
BR
Brazil
Prior art keywords
polypeptide
pharmaceutical combination
treating
nucleic acid
methods
Prior art date
Application number
BR112015027528A
Other languages
English (en)
Other versions
BR112015027528B1 (pt
Inventor
James Carpenter Andrew
Neil Hunter Robert Iii
Thomas Dock Steven
P Srivastava Ved
Wu Yulin
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112015027528A2 publication Critical patent/BR112015027528A2/pt
Publication of BR112015027528B1 publication Critical patent/BR112015027528B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1 / 1 resumo “polipeptãdeo, combinaã‡ãƒo farmacãšutica, mã‰todos de tratamento de um distãšrbio metabã“lico e de obesidade, uso de um polipeptãdeo ou de uma combinaã‡ãƒo farmacãšutica, molã‰cula de ãcido nucleico, vetor de expressãƒo, e, cã‰lula hospedeira” a presente invenã§ã£o refere-se aos novos anã¡logos de pyy que tãªm um perfil terapãªutico aprimorado quando comparados com o pyy nativo de humano. estes novos anã¡logos de pyy sã£o ãºteis no tratamento de obesidade, diabetes e outros distãºrbios.
BR112015027528-1A 2013-05-02 2014-04-30 Polipeptídeo, forma de sal, combinação farmacêutica e composição farmacêutica BR112015027528B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818624P 2013-05-02 2013-05-02
US61/818,624 2013-05-02
PCT/IB2014/061123 WO2014178018A1 (en) 2013-05-02 2014-04-30 Therapeutic peptides

Publications (2)

Publication Number Publication Date
BR112015027528A2 true BR112015027528A2 (pt) 2017-12-05
BR112015027528B1 BR112015027528B1 (pt) 2023-02-14

Family

ID=50842285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027528-1A BR112015027528B1 (pt) 2013-05-02 2014-04-30 Polipeptídeo, forma de sal, combinação farmacêutica e composição farmacêutica

Country Status (20)

Country Link
US (2) US20160108098A1 (pt)
EP (1) EP2992008B1 (pt)
JP (1) JP2016519130A (pt)
KR (1) KR20160003848A (pt)
CN (1) CN105263957A (pt)
AR (1) AR096162A1 (pt)
AU (1) AU2014261111B2 (pt)
BR (1) BR112015027528B1 (pt)
CA (1) CA2909045C (pt)
CL (1) CL2015003199A1 (pt)
EA (1) EA201591839A1 (pt)
ES (1) ES2732291T3 (pt)
HK (1) HK1214829A1 (pt)
MX (1) MX2015015249A (pt)
PE (1) PE20151808A1 (pt)
RU (1) RU2015144632A (pt)
SG (1) SG11201508469YA (pt)
TW (1) TW201534616A (pt)
UY (1) UY35548A (pt)
WO (1) WO2014178018A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
WO2014178018A1 (en) * 2013-05-02 2014-11-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
US10246497B2 (en) * 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
MY187047A (en) 2015-06-12 2021-08-27 Novo Nordisk As Selective pyy compounds and uses thereof
US10808253B2 (en) * 2015-12-28 2020-10-20 Idemitsu Kosan Co., Ltd. Peptide tag and tagged protein including same
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
EP3592376A1 (en) 2017-03-08 2020-01-15 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TW202208410A (zh) * 2018-11-01 2022-03-01 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
JP2023513658A (ja) * 2019-12-04 2023-04-03 ザ スクリプス リサーチ インスティテュート Ｇｌｐ２受容体アゴニストおよびその使用方法
CA3175725A1 (en) * 2020-04-17 2021-10-21 William Blackwell Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use
BR112022025623A2 (pt) 2020-08-07 2023-03-07 Boehringer Ingelheim Int Agonistas solúveis de receptores de npy2
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
DE69838791T3 (de) 1997-08-08 2011-06-22 Amylin Pharmaceuticals, Inc., Calif. Neue exendinagonist verbindungen
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2004505761A (ja) 2000-08-15 2004-02-26 ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 微小粒子
KR100989647B1 (ko) * 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1799241A2 (en) * 2004-09-24 2007-06-27 Merck & Co., Inc. Combination therapy for the treatment of obesity
MX2007006830A (es) * 2004-12-13 2008-02-07 Amylin Pharmaceuticals Inc Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
KR20080110852A (ko) * 2006-03-23 2008-12-19 아밀린 파마슈티칼스, 인크. 대사질환 치료용 엔도테린 및 엔도테린 수용체 작용제
US20120276098A1 (en) 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life
WO2011050008A2 (en) * 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
EP2600887A4 (en) * 2010-07-09 2014-01-22 Amylin Pharmaceuticals Llc MICROCRYSTALLINE AGONISTS OF Y-RECEPTORS
GB201101459D0 (en) * 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
WO2014178018A1 (en) * 2013-05-02 2014-11-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
US10246497B2 (en) * 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof

Also Published As

Publication number Publication date
TW201534616A (zh) 2015-09-16
US20140329742A1 (en) 2014-11-06
ES2732291T3 (es) 2019-11-21
EP2992008B1 (en) 2019-04-10
JP2016519130A (ja) 2016-06-30
AU2014261111B2 (en) 2017-03-16
RU2015144632A (ru) 2017-06-07
CN105263957A (zh) 2016-01-20
AU2014261111A1 (en) 2015-11-19
SG11201508469YA (en) 2015-11-27
EP2992008A1 (en) 2016-03-09
EA201591839A1 (ru) 2016-05-31
AR096162A1 (es) 2015-12-09
CL2015003199A1 (es) 2016-05-06
UY35548A (es) 2014-11-28
BR112015027528B1 (pt) 2023-02-14
US9441023B2 (en) 2016-09-13
PE20151808A1 (es) 2015-12-16
WO2014178018A1 (en) 2014-11-06
HK1214829A1 (zh) 2016-08-05
MX2015015249A (es) 2016-02-09
CA2909045C (en) 2022-12-06
US20160108098A1 (en) 2016-04-21
KR20160003848A (ko) 2016-01-11
CA2909045A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
BR112015027528A2 (pt) polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
BR112017019054A2 (pt) métodos para o tratamento de pele
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
BR112017012621A2 (pt) peptídeos cíclicos com seletividade de ligação nervosa melhorada, nanopartículas ligadas com os referidos peptídeos cíclicos, e o uso dos mesmos para a produção de imagens de tecido nervoso in vivo em tempo real
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
BR112016029906A8 (pt) formulação líquida, uso de formulação terapêutica líquida, uso de formulação terapêutica líquida injetável, método de melhoria da estabilidade de uma formulação proteica líquida e método de melhoria de um processo relacionado a proteínas
MX2016015997A (es) Preparacion y uso de beta-d-nicotinamida ribosido cristalina.
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
BR112015022507A2 (pt) ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados
BR112016022465A2 (pt) agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4
BR112014027165A2 (pt) antagonistas de st2l e métodos de uso
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112014006684A2 (pt) análogos de glucagon
BR112017019378A2 (pt) análogos de amilina
BR112015022808A8 (pt) farinha de aveia de grãos integrais altamente dispersáveis e com um teor de avenantramida aumentado, e método de preparação das mesmas
MX2015013939A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112017013300A2 (pt) alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições.
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
BR112015025892A2 (pt) inibidores de metap2 e métodos para tratar obesidade
BR112014031841A2 (pt) formulação farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2014, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB)